Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A R Thompson

Showing results (181-190 of 203) with videos related to

Pageof 21
Sort By:
Diabetes Research and Clinical Practice|March 1, 1985
HLA, complement C2, C4, properdin factor B and glyoxalase types in South Indian diabeticsR L Kirk, P R Ranford, S W Serjeantson, et al.
Science (New York, N.Y.)|October 1, 1993
In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogsM A Kay, S Rothenberg, C N Landen, et al.
QJM : Monthly Journal of the Association of Physicians|March 11, 2009
Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trialJ K Baillie, A A R Thompson, J B Irving, et al.
Journal of Medicinal Chemistry|May 15, 1992
Leukotriene B4 receptor antagonists: the LY255283 series of hydroxyacetophenonesD K Herron, T Goodson, N G Bollinger, et al.
Journal of Thrombosis and Haemostasis : JTH|August 14, 2010
In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control studyC L Kempton, J M Soucie, C H Miller, et al.
Blood|October 1, 1987
Carrier testing in hemophilia B with an immunoassay that distinguishes a prevalent factor IX dimorphismK J Smith, A R Thompson, B A McMullen, et al.
British Journal of Haematology|September 1, 1996
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study GroupsD Menache, D L Aronson, F Darr, et al.
Thorax|June 28, 2012
A decoy receptor 3 analogue reduces localised defects in phagocyte function in pneumococcal pneumoniaHelen M Marriott, Marc Daigneault, Alfred A R Thompson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 8, 2010
Hypoxia selectively inhibits respiratory burst activity and killing of Staphylococcus aureus in human neutrophilsNaomi N McGovern, Andrew S Cowburn, Linsey Porter, et al.
Nature Genetics|July 1, 1997
Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectorsR O Snyder, C H Miao, G A Patijn, et al.
Pageof 21

Showing results (181-190 of 203) with videos related to

Sort By:
Pageof 21
Diabetes Research and Clinical Practice|March 1, 1985
HLA, complement C2, C4, properdin factor B and glyoxalase types in South Indian diabeticsR L Kirk, P R Ranford, S W Serjeantson, et al.
Science (New York, N.Y.)|October 1, 1993
In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogsM A Kay, S Rothenberg, C N Landen, et al.
QJM : Monthly Journal of the Association of Physicians|March 11, 2009
Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trialJ K Baillie, A A R Thompson, J B Irving, et al.
Journal of Medicinal Chemistry|May 15, 1992
Leukotriene B4 receptor antagonists: the LY255283 series of hydroxyacetophenonesD K Herron, T Goodson, N G Bollinger, et al.
Journal of Thrombosis and Haemostasis : JTH|August 14, 2010
In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control studyC L Kempton, J M Soucie, C H Miller, et al.
Blood|October 1, 1987
Carrier testing in hemophilia B with an immunoassay that distinguishes a prevalent factor IX dimorphismK J Smith, A R Thompson, B A McMullen, et al.
British Journal of Haematology|September 1, 1996
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study GroupsD Menache, D L Aronson, F Darr, et al.
Thorax|June 28, 2012
A decoy receptor 3 analogue reduces localised defects in phagocyte function in pneumococcal pneumoniaHelen M Marriott, Marc Daigneault, Alfred A R Thompson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 8, 2010
Hypoxia selectively inhibits respiratory burst activity and killing of Staphylococcus aureus in human neutrophilsNaomi N McGovern, Andrew S Cowburn, Linsey Porter, et al.
Nature Genetics|July 1, 1997
Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectorsR O Snyder, C H Miao, G A Patijn, et al.
Pageof 21